Timolo 0.5% /dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients

Acta Ophthalmologica Scandinavica

Volumn 81, Issue 4, 2003, Pages 349-354

  Kałuz̊ny, Jakub J ^a   Szaflik, Jerzy ^b   Czechowicz Janicka, Krystyna ^c   Kałuz̊ny, Józef ^a   Orzalkiewicz, Alicja ^a   Zaleska, Anna ^b   Krajewska, Malgorzata ^c   Stewart, Jeanette A ^d   Leech, Jessica N ^d   Stewart, William C ^d,e  

^a Klinika Okulistyki   (Poland)

^b Okulistyczny Szpital Kliniczny   (Poland)

^c Centrum Medyczne Osteomed   (Poland)

^d Pharmaceutical Research Network   (United States)

^e UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Timolol dorzolamide; Timolol pilocarpine

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; FOTIL; PILOCARPINE; TIMOLOL; TIMOLOL MALEATE; ANTIHYPERTENSIVE AGENT; DORZOLAMIDE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TISSUE LEVEL; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TASTE DISORDER; VISUAL ACUITY; VISUAL IMPAIRMENT; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED; SAFETY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PILOCARPINE; PROSPECTIVE STUDIES; SAFETY; SULFONAMIDES; THIOPHENES; TIMOLOL; TREATMENT OUTCOME;

EID: 0043173716     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.2003.00097.x     Document Type: Article

References (35)

1. Advanced Glaucoma Intervention Study (AGIS) (2000): The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429-440.
2. Book SA (1978): Essentials of Statistics. New York: McGraw-Hill 117-122, 205-215.
3. Boyle JE, Ghosh K, Gieser DK & Adamsons IA (1999): A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology 106: 10-16.
4. Choudhri S, Wand M & Shields MB (2000): A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 130: 832-833.
5. Clineschmidt CM, Snyder D & Adamsons I (1998): A randomized trial comparing the dorzolamide/timolol combination to monotherapy with timolol or dorzolamide in patients inadequately controlled on timolol alone. Invest Ophthalmol Vis Sci 39 (Suppl): 707.
6. Demailly P, Allaire C, Bron V & Trinquand C (1995): Effectiveness and tolerance of β-blocker/pilocarpine combination eye drops in primary open-angle glaucoma and high intraocular pressure. J Glaucoma 4: 235-241.
7. Drance SM, Bensted M & Schulzer M (1974): Pilocarpine and intraocular pressure. Duration of effectiveness of 4% and 8% pilocarpine instillation. Arch Oplithalmol 91: 104-106.
8. Duff GR (1987): A double-masked crossover study comparing the effects of carteolol 1% and 2% on intraocular pressure. Acta Ophthalmol Scand 65: 618-621.
9. Harris LS & Galin MA (1970): Dose-response analysis of pilocarpine-induced ocular hypotension. Arch Ophthalmol 84: 605-608.
10. Harris LS & Galin MA (1971): Effect of ocular pigmentation on hypotensive response to pilocarpine. Am J Ophthalmol 72: 923-925.
11. Kitazawa Y, Azuma I & Iwata K (1994): Dorzolamide, a topical anhydrase inhibitor: a 2-week dose-response study in patients with glaucoma or ocular hypertension. J Glaucoma 3: 275-279.
12. Konstas AGP, Mantziris DA & Stewart WC (1997): Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 115: 182 185.
13. Konstas AGP, Papapanos P, Tersis I, Houliara D & Stewart WC (2003): Twenty-four hour diurnal curve comparison of commercially available latanoprost 0.005% versus timolol/dorzolamide fixed combination. Ophthalmology. in press.
14. Konstas AGP, Stewart WC, Topouzis F, Tersis I, Holmes KT & Stangos NT (2001): Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol 131: 729-733.
15. Krill AE & Newell FW (1964): Effects of pilocarpine on ocular tension dynamics. Am J Ophthalmol 57: 34.
16. Laibovitz R, Strahlman ER, Barber BL & Strohmaier KM (1995): Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 4: 306-313.
17. Lippa EA, Carlson L-E, Ehinger B et al. (1992): Dose response and duration of action of dorzolamide, a topical anhydrase inhibitor. Arch Ophthalmol 110: 495-499.
18. Maclure GM, Vogel R, Sturm A & Binkowitz B (1989): Effect on the 24-hour diurnal curve of intraocular pressure of a fixed ratio combination of timolol 0.5% and pilocarpine 2% in patients with COAG not controlled on timolol 0.5%. Br J Ophthalmol 73: 827-831.
19. Mao LK, Stewart WC & Shields MB (1991): Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 111: 51-55.
20. Mundorf TK, Cate EA, Sine CS, Otero DW, Stewart JA & Stewart WC (1998): The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocular Pharm Therap, 14: 129-135.
21. Puustjärvi TJ & Repo LP (1992): Timolol-pilocarpine fixed-ratio combinations in the treatment of chronic open-angle glaucoma. A controlled multicentre study of 48 weeks. Arch Ophthalmol 110 (12): 1725-1729.
22. Siegel S (1956): Non Parametric Statistics. Series in Psychology. New York: McGraw-Hill 63-67.
23. Söderström MB, Wallin O, Granström PA & Thorburn W (1989): Timolol-pilocarpine combined versus timolol and pilocarpine given separately. Am J Ophthalmol 107: 465-470.
24. Stewart WC, Chorak RP, Hunt HH & Sethuraman G (1993): Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 116: 176-181.
25. Stewart WC, Day DG, Stewart JA, Schuhr J & Latham KE (2001): The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 131: 631-635.
26. Stewart WC, Kolker AF, Sharpe ED, Day DG, Holmes KT, Leech JN, Johnson M & Cantrell JB (2000a): Factors associated with longterm progression or stability in primary open-angle glaucoma. Am J Ophthalmol 130: 274-279.
27. Stewart WC, Sharpe ED, Harbin TS Jr, Pastor SA, Day DG, Holmes KT & Stewart JA (2000b): Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol 129: 723-727.
28. Strahlman E, Tipping R & Vogel R (1995): A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 113: 985-986.
29. Strahlman E, Tipping R & Vogel R (1996a): A 6-week dose response study of the ocular hypotensive effect of dorzolamide with a 1-year extension. International Dorzolamide Study Group. Am J Ophthalmol 122: 183-194.
30. Strahlman ER, Vogel R, Tipping R, Clineschmidt CM & the Dorzolamide Additivity Study Group (1996b): The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 103: 1283-1293.
31. Strohmaier K, Snyder E, DuBiner H & Adamsons I (1998): The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology 105: 1936-1944.
32. Sverrisson T, Gross R, Pearson J, Rusk C, Adamsons I, the United States Patient Preference Study Group & the International Patient Preference Study Group (1999): The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. J Glaucoma 8: 315-324.
33. Uusitalo RJ & Palkama A (1994): Efficacy and safety of timolol/pilocarpine combination drops in glaucoma patients. Acta Ophthalmol (Copenh) 72: 496-504.
34. Wilkerson M, Cyrlin M, Lippa EA et al. (1993): Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 111: 1343-1350.
35. Zadok D, Geyer O, Zadok J, Lazar M, Krawoski D & Nemet P (1994): Combined timolol and pilocarpine versus pilocarpine alone and timolol alone in the treatment of glaucoma. Am J Ophthalmol 117: 728-731.